Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed August 2026
Key Takeaways
- ATTR-CM is a distinct progressive amyloid cardiomyopathy, not simply another variant of HFpEF.
- Recognition commonly lags the disease because early features overlap with more common cardiac conditions; suspicion rises when cardiac and extracardiac clues cluster rather than appear in isolation.
- Once established, ATTR-CM typically progresses over years with accumulating diastolic dysfunction, functional decline, and increasing risk of heart failure events.
- Diagnosis, disease classification (wild-type versus hereditary and exclusion of amyloid light chain (AL) amyloidosis), and long-term treatment continuity are most valuable when addressed early.
ATTR-CM as an Infiltrative Cardiomyopathy
ATTR-CM is a progressive infiltrative cardiomyopathy in which transthyretin amyloid accumulates in the myocardium and gradually reduces cardiac reserve. It often presents through a heart failure lens—exertional dyspnea, fatigue, and congestion—but the underlying biology and clinical tempo are different from routine HFpEF. Transthyretin is a transport protein that can misfold and deposit as amyloid fibrils; in ATTR-CM, those deposits stiffen the ventricular walls and impair filling. The disease occurs in a wild-type form that’s seen mainly in older adults and a hereditary form driven by pathogenic transthyretin (TTR) variants.
Why Recognition Lags the Disease
Recognition is frequently delayed because the early features overlap with far more common diseases. Increased left ventricular wall thickness, congestion, atrial arrhythmias, conduction disease, a history of bilateral carpal tunnel syndrome, or neuropathic clues each have many possible explanations. They become far more meaningful when they cluster in the same patient rather than appearing one at a time. That pattern recognition—and an appreciation of where ATTR-CM should be suspected—is central to identifying patients who warrant an ATTR-CM workup.
How ATTR-CM Progresses over Time
Once established, ATTR-CM usually unfolds over years rather than weeks, with accumulating diastolic dysfunction, declining functional capacity, and a rising burden of heart failure events. The natural history is one of gradual narrowing of reserve, punctuated by decompensations, arrhythmia, and progressive limitation. Because the trajectory is progressive, the potential value of disease-modifying intervention depends in part on how early the disease is identified, while long-term management requires sustained follow-up.
Why Early Diagnosis and Continuity Matter
Current disease-modifying therapy for ATTR-CM is designed to slow progression, not to reverse amyloid that has already deposited or to restore fixed structural damage. That single fact reframes the whole care pathway: earlier confirmation and classification may allow disease-modifying therapy to be introduced before more advanced cardiac impairment has developed. Sustained, multidisciplinary follow-up—and the treatment continuity that supports it— therefore becomes an important part of long-term management rather than an optional extra. The appropriate next step following clinical suspicion is structured diagnostic confirmation.
Frequently Asked Questions
Is ATTR-CM the same as HFpEF?
No. ATTR-CM often presents with preserved ejection fraction and can resemble HFpEF, but it’s a specific infiltrative disease caused by transthyretin amyloid deposition. The distinction matters because ATTR-CM has its own diagnostic pathway and disease-specific therapy, whereas generic HFpEF management alone doesn't address the underlying amyloid process.
What are the two main types of ATTR-CM?
The two main types are wild-type ATTR-CM, which isn't inherited and occurs mainly in older adults, and hereditary (variant) ATTR-CM, which is caused by a pathogenic TTR gene variant. Distinguishing them affects family screening and genetic counseling, so classification is part of a complete diagnosis.
Why is ATTR-CM often diagnosed late?
Its early signs, such as wall thickening, congestion, arrhythmia, conduction disease, and carpal tunnel syndrome, are individually nonspecific and common. The diagnosis is usually missed until several of these clues are recognized together as a pattern that warrants a structured amyloidosis workup.
Can ATTR-CM be cured?
There is currently no established cure for ATTR-CM. Available disease-modifying therapy aims to slow progression rather than reverse established amyloid deposition, which is why early diagnosis and sustained long-term treatment and follow-up are emphasized.
Related Reading
Part of the Spotlight On ATTR-CM resource center.
Understand the Disease
Confirm the Diagnosis
See the Evidence
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- Baseline Characteristics and Secondary Medication Adherence Among Medicare Patients Diagnosed with ATTR-CM and/or Receiving Tafamidis Prescriptions. Journal of Managed Care & Specialty Pharmacy
- Best Practices in Specialized Amyloidosis Centers in the United States. Clinical Medicine Insights: Cardiology
- Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. Journal of the American College of Cardiology
- Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy. JACC Heart Failure
This content is intended for healthcare professionals for educational purposes and isn't a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.